Cytokinetics receives FDA approval for MYQORZO tablets for oHCM

In patients suffering with oHCM, myosin inhibition with MYQORZO lowers left ventricular outflow tract obstruction and cardiac contractility. Credit: NMK-Studio/Shutterstock.com.